Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Journal of Natural Medicines (English Ed.) ; (6): 648-653, 2014.
Article Dans Anglais | WPRIM | ID: wpr-812220

Résumé

AIM@#The hypoglycemic and hypolipidemic effects of the methanol extract of Brassica oleracea var. capitata (MEB) was evaluated in alloxan-induced diabetic rabbits.@*METHOD@#The study was conducted on twenty-eight healthy white rabbits of either sex. All animals were equally divided into four groups. After confirmation of hyperglycemia, the animals of the treated and standard groups were administered MEB (500 mg·kg(-1)) and glibenclamide (10 mg·kg(-1)), respectively for 15 and 30 days. The animals of the normal and diabetic controls received normal saline 1 mL/day equivalent to the volume of doses given to the test and standard animals. Biochemical tests were performed at the end of dosing, i.e. the 16(th) and 31(st) days.@*RESULTS@#The MEB revealed a decrease of 106.6 mg·dL(-1) in fasting blood glucose as compared to diabetic control, which was almost comparable to glibenclamide; both of these changes were highly significant. The decrease in total cholesterol and low density lipoprotein was 94.3 and 96.5 mg·dL(-1), respectively, whereas the high-density lipoprotein was increased by 26.7 mg·dL(-1), as compared to diabetic control. All of the changes in lipid profile were statistically significant.@*CONCLUSION@#These results suggest the potential of MEB as a hypoglycemic and hypolipidemic agent.


Sujets)
Animaux , Femelle , Mâle , Lapins , Glycémie , Métabolisme , Brassica , Cholestérol , Sang , Diabète expérimental , Sang , Traitement médicamenteux , Hypoglycémiants , Pharmacologie , Utilisations thérapeutiques , Hypolipémiants , Pharmacologie , Utilisations thérapeutiques , Lipoprotéines , Sang , Phytothérapie , Extraits de plantes , Pharmacologie , Utilisations thérapeutiques , Triglycéride , Sang
2.
Hamdard Medicus. 1998; 41 (1): 55-57
Dans Anglais | IMEMR | ID: emr-48019

Résumé

A new chemically synthesized piperidine derivative i.e. 1-methyl-1 [4-chloro] phenacyl-4-hydroxy piperidinium bromide was tested for analygesic activity in intact albino mice by tail flick latency in tail immersion method [Di Stasi et al., 1988]. The compound was administered orally in the doses of 50 mg/kg. Pethidine HCI 50 mg/kg was used as a reference drug. Control animals received only the vehicle. The result indicates that this compound exhibits highly significant analgesic activity


Sujets)
Animaux de laboratoire , Mâle , Femelle , Analgésiques/synthèse chimique , Souris
3.
Hamdard Medicus. 1998; 41 (4): 53-55
Dans Anglais | IMEMR | ID: emr-48082

Résumé

Two chemically synthesized piperidinium derivatives i.e. 1-methyl-1 [4-nitro] phenacy1 4-hydroxy piperidinium bromide and 1-methyl-1 [4-bromo] phenacyl 4-hydroxy piperidinium bromide were tested for their analgesic activity in intact albino mice by tail flick latency in tail immersion method. All the compounds were administered orally in the doses of 50 mg/kg. Pethidine 50 mg/kg was used as a reference drug for comparison purpose. The results showed that both of these compounds exhibit a highly significant activity


Sujets)
Animaux de laboratoire , Pipéridines/pharmacologie , Souris , Analgésiques
SÉLECTION CITATIONS
Détails de la recherche